Evidence signal01
Semax had more than a purely mechanistic record
FDA reviewed human references involving the nominated neurological conditions, including intranasal administration.
FDA briefing pp. 22–28Day 2 recordPCAC favorable
Peptide dossier / July 23–24, 2026Semax
Semax had a wider pharmacology literature and limited clinical references, but FDA found the direct clinical record too small and methodologically weak for the nominated uses.
Decision boundaryPCAC advice is not FDA approval, does not establish safety or effectiveness, and did not itself place either form on the 503A Bulks List.
Editorial review
The central tension in this record.
FDA staff recommended against both forms; PCAC voted favorably on both form-level questions.
Decisive limitation02
The direct clinical evidence remained weak
The available studies were few, small and insufficiently controlled or reported; nonclinical volume did not solve the clinical-evidence gap.
FDA briefing pp. 25–28, 42–43PeptideBase read
The committee outcome belongs beside the evidence record—not on top of it. A favorable advisory vote describes the panel’s recommendation on compounding eligibility; it does not erase FDA’s characterization, route-match or human-evidence concerns.
The case made in the room
Named speakers. Their strongest argument. Then the record check.
These are attributed testimony arguments, not PeptideBase endorsements. Each one is paired with the most relevant FDA answer and an explicit assessment of what the evidence can—and cannot—carry.
4named speaker moments
100%recording checked
Only named, source-reconciled speaker moments that were checked against the recording appear here. Statements remain attributed arguments unless the underlying evidence was independently established; no machine-caption wording is published as a quotation.
01Supports listing
Alex Tatem, MD
Board-certified urologist; fellowship-trained in male fertility, microsurgery and sexual medicine
Verify credentialsAttributed testimony
The foreign-use and stroke-literature case
Tatem cited Russian clinical-use history and stroke literature as reasons to take Semax seriously. Those claims were presented as support for listing; the underlying foreign sources and their methodological quality were not resolved within this hearing record.
semax session · attributed argument, not an established factAudio-checked paraphrasePlay the source06:28:31–06:29:18
02Supports listing
Ricardo Rosselló, PhD
Biomedical scientist and former Governor of Puerto Rico
Verify credentialsAttributed testimony
The access argument
Rosselló argued that removing supervised clinical access without a replacement can redirect patients toward an unregulated market.
Attributed testimony
The online-market safety warning
Gonzalez relayed a message about a patient who believed he had experienced a seizure after injecting a peptide obtained online. The example was not specific to Semax and does not establish causation.
Semax session · anecdote not specific to SemaxAudio-checked paraphrasePlay the source06:47:12–06:47:39
04Opposes listing
Peter Lurie, MD, MPH
President and Executive Director, Center for Science in the Public Interest; former FDA Associate Commissioner
Verify credentialsAttributed testimony
The hearing-wide case against all seven
Lurie said CSPI opposed adding all seven substances. He argued that the FDA criteria had not been met, that compounded products could create consumer risks, and that listing could weaken incentives for development through the standard drug-approval pathway.
Opening public hearing · explicitly applied to all seven substancesAudio-checked paraphrasePlay the source00:57:09–00:57:55
Foreign-use history and stroke literature make Semax a meaningful candidate for supervised access.
Foreign-use history and unresolved literatureWhat supports it
The hearing described Russian use and clinical literature. The underlying sources, methods and correspondence to the exact nominated forms, routes and uses were not fully resolved in the reviewed record.
FDA’s answer
FDA found insufficient evidence supporting effectiveness for the nominated uses and insufficient clinical information to characterize safety.
FDA Day 2 presentation · 07:09:13PeptideBase assessment
Foreign-use history may justify closer source review. Without matched, source-resolved evidence, it cannot carry the effectiveness or safety conclusion.
Why the judgments diverged
Foreign-use history and harm reduction met a route-matched evidence test.
The favorable majority appears to have given weight to foreign-use history, neurobiological rationale and the argument for supervised access. FDA required evidence tied to the exact nominated forms, routes and uses and found it insufficient.
Editorial inference from the hearing record—not an attributed rationale for every voterClaim versus record
What the official material supports—and what it does not.
These are recurring propositions in the wider peptide discussion, not attributed speaker quotations.
Recurring claim
A large pharmacology literature establishes clinical effectiveness.
Official record
FDA said only two available clinical references informed the effectiveness review for the nominated uses and that they lacked sufficient study-design detail.
What it does not establish
FDA briefing pp. 22–28, 42–43A large nonclinical literature does not replace controlled evidence for the exact chemical form, route and clinical use.
Recurring claim
The migraine and trigeminal-neuralgia studies showed reliable analgesic benefit.
Official record
FDA described the relevant studies as small, uncontrolled and open-label; it said Semax did not resolve pain for the majority of subjects in those analyses.
What it does not establish
FDA briefing pp. 25–28The studies’ small samples, missing controls, unclear scales and incomplete endpoint reporting prevent confident effectiveness conclusions.
Evidence architecture
Eight questions applied consistently.
“Absent” means FDA said it did not identify that evidence within this evaluation. It is not a universal claim that no evidence exists anywhere.
| Evidence question | Status | FDA-record summary | Locator |
|---|---|---|---|
| Human clinical evidence | limited | FDA relied on two clinical references with limited study-design detail. | Briefing pp. 22–28, 42–43 |
| Nonclinical evidence | indirect | A substantial pharmacology literature existed, but it did not establish clinical effectiveness for the nominated uses. | Briefing pp. 28–36 |
| Exact-form match | contested | The withdrawn nominations were inconsistent about free base versus acetate. | Briefing pp. 6–17 |
| Nominated-route match | limited | Some intranasal evidence aligned with one proposed route; the record did not establish the full intranasal/SC product set. | Briefing pp. 6, 22–28 |
| Evaluated-use match | limited | Small studies addressed the nominated conditions but were methodologically inadequate or showed limited effect. | Briefing pp. 22–28 |
| Product characterization | limited | FDA considered both forms not well characterized. | Briefing pp. 7–18 |
| Human safety | limited | FDA found insufficient clinical information to characterize safety and immunogenicity. | Briefing pp. 36–43 |
| Historical compounding use | limited | FDA found the extent of historical use in compounding unclear. | Briefing pp. 18–22 |
Qualitative evidence map · no numerical score · scoped to FDA’s July 2026 evaluation
FDA findings
Five parts of the staff case.
01characterizationBoth Semax free base and Semax acetate were considered not well characterized.Day 2 pp. 116, 119
07:00:0102effectivenessFDA found insufficient evidence supporting effectiveness for the nominated uses.Day 2 pp. 126–131
07:09:1303safetyFDA found insufficient clinical information to characterize safety and raised potential immunogenicity concerns.Day 2 pp. 132–139
07:20:4404historical useFDA found the extent of historical use in compounding unclear.Day 2 pp. 140–144
07:24:0405recommendationFDA proposed that neither Semax free base nor Semax acetate be included on the 503A Bulks List.Day 2 pp. 144–145
07:25:40
07:00:0102effectivenessFDA found insufficient evidence supporting effectiveness for the nominated uses.Day 2 pp. 126–131
07:09:1303safetyFDA found insufficient clinical information to characterize safety and raised potential immunogenicity concerns.Day 2 pp. 132–139
07:20:4404historical useFDA found the extent of historical use in compounding unclear.Day 2 pp. 140–144
07:24:0405recommendationFDA proposed that neither Semax free base nor Semax acetate be included on the 503A Bulks List.Day 2 pp. 144–145
07:25:40
What changes the assessment
Open evidence gaps and direct sources.
A useful dossier should show the reader what evidence could materially strengthen or weaken the current read.
01
Controlled trials of the exact form, route and nominated neurological uses
02
Clinical safety, immunogenicity and pharmacokinetic evidence
03
Validated identity, impurity and finished-product specifications
Decision boundaryPCAC advice is not FDA approval, does not establish safety or effectiveness, and did not itself place either form on the 503A Bulks List.
Continue the record
View all sevenRelated peptide dossiers
Day 1
BPC-157
The official record contains a limited human signal and substantial nonclinical literature, but the exact form, dosage form, route, duration and safety questions remain unresolved.
Open dossierDay 1KPV
KPV’s official-record case is primarily mechanistic and nonclinical. FDA said it found no human administration or exposure data by any route.
Open dossierDay 1TB-500
The central technical issue is identity: FDA treated the seven-amino-acid TB-500 fragment as distinct from full-length thymosin beta-4 and found no direct human TB-500 evidence.
Open dossier